Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › ALXO
SILVERARC CAPITAL MANAGEMENT, LLC position in ALXO
ALX ONCOLOGY HLDGS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 6,565,960 shares of ALXO (ALX ONCOLOGY HLDGS INC) in its Q3 2026 13F filing — a position valued at US$9.1M, representing 1.16% of its reported portfolio and ranking #24 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ALXO holdings in 3 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's ALXO position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in ALXO in Q2 2024 at 167,900 shares (US$1.0M). The position peaked in Q2 2026 at 5,744,757 shares, worth US$11.9M. Across 3 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 6,565,960 shares valued at US$9.1M — an increase of 821,203 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 167.90K | $1.01M | New |
| Q2 2026 | 5.74M | $11.89M | New |
| Q3 2026 | 6.57M | $9.13M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALXO and 13F data
ALXO (ALX ONCOLOGY HLDGS INC) is a Health Care company. 34 other funds we track also report a position in ALXO — the largest reported positions include venBio Partners LLC (US$26.7M), Redmile Group, LLC (US$15.3M), TCG Crossover Management, LLC (US$11.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALXO
- venBio Partners LLC 12.88M sh · $26.67M · Q2 2026
- Redmile Group, LLC 7.39M sh · $15.30M · Q2 2026
- TCG Crossover Management, LLC 5.66M sh · $11.71M · Q2 2026
- 5AM Venture Management, LLC 3.06M sh · $6.33M · Q2 2026
- Almitas Capital LLC 2.94M sh · $6.08M · Q2 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held ALXO?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ALXO holdings in 3 of the last 10 reported quarters, going back to Q2 2024.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ALXO?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 6.57M shares of ALXO (ALX ONCOLOGY HLDGS INC), valued at $9.13M, representing 1.16% of its reported portfolio and ranking #24.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ALXO?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in ALXO. The position peaked in Q2 2026 at 5.74M shares.
Which other funds hold ALXO?
Other major institutional holders of ALXO include venBio Partners LLC, Redmile Group, LLC, TCG Crossover Management, LLC, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.